Genovese Burford & Brothers Wealth & Retirement Plan Management’s Sarepta Therapeutics SRPT Stock Holding History

Genovese Burford & Brothers Wealth & Retirement Plan Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-100	Closed	-$13K	–	331
2018 Q2	$13K	Hold	100	–	–	﹤0.01%	295
2018 Q1	$7K	Buy	+100	New	+$6.67K	﹤0.01%	345
2017 Q4	–	Sell	-100	Closed	-$4K	–	423
2017 Q3	$4K	Hold	100	–	–	﹤0.01%	346
2017 Q2	$3K	Hold	100	–	–	﹤0.01%	345
2017 Q1	$3K	Hold	100	–	–	﹤0.01%	386
2016 Q4	$3K	Buy	+100	New	+$4.02K	﹤0.01%	431

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Genovese Burford & Brothers Wealth & Retirement Plan Management's SRPT Position: Q3 2018 in Review

Genovese Burford & Brothers Wealth & Retirement Plan Management sold out of Sarepta Therapeutics (SRPT) in Q3 2018, closing a stake of 100 shares — an estimated $13K sold.

Genovese Burford & Brothers Wealth & Retirement Plan Management first reported a position in SRPT in Q4 2016 and held it in 6 quarters. The position peaked at $13K in Q2 2018. 345 funds tracked by Wall St. Rank hold SRPT as of Q3 2018.

Genovese Burford & Brothers Wealth & Retirement Plan Management reported no remaining Sarepta Therapeutics position as of Q3 2018 after selling out during the quarter.
Genovese Burford & Brothers Wealth & Retirement Plan Management sold 100 Sarepta Therapeutics shares in Q3 2018, an estimated $13K.
Genovese Burford & Brothers Wealth & Retirement Plan Management first reported a position in Sarepta Therapeutics in Q4 2016 and held it in 6 quarters.
Genovese Burford & Brothers Wealth & Retirement Plan Management's Sarepta Therapeutics position peaked at $13K in Q2 2018.
345 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2018.

Based on Genovese Burford & Brothers Wealth & Retirement Plan Management's 13F filing for Q3 2018, filed 13 Nov 2018.